{"id":2159,"date":"2017-06-06T17:00:29","date_gmt":"2017-06-06T11:30:29","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2159"},"modified":"2021-07-24T12:56:46","modified_gmt":"2021-07-24T07:26:46","slug":"notizia-42","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-42","title":{"rendered":"Dendreon touts; Zytiga slashes risk; Lynparza posts; Dacomitinib wins; Alecensa trounces"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69f8e5ecb3a73\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69f8e5ecb3a73\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-42\/#Dendreon_touts_T-cell_response_data_for_prostate_cancer_vaccine_Provenge\" >Dendreon touts T-cell response data for prostate cancer vaccine Provenge<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-42\/#Johnson_Johnsons_Zytiga_slashes_death_risk_by_38_in_earlier-stage_prostate_cancer_patients\" >Johnson &amp; Johnson&#8217;s Zytiga slashes death risk by 38% in earlier-stage prostate cancer patients<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-42\/#AstraZenecas_Lynparza_posts_42_survival_win_in_breast_cancer\" >AstraZeneca&#8217;s Lynparza posts 42% survival win in breast cancer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-42\/#Pfizers_two-time_loser_dacomitinib_finally_wins_in_phase_3_against_AstraZenecas_Iressa\" >Pfizer&#8217;s two-time loser dacomitinib finally wins in phase 3 against AstraZeneca&#8217;s Iressa<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-42\/#Roches_Alecensa_trounces_Pfizers_Xalkori_in_head-to-head_ALK_matchup\" >Roche&#8217;s Alecensa trounces Pfizer&#8217;s Xalkori in head-to-head ALK matchup<\/a><\/li><\/ul><\/nav><\/div>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Dendreon_touts_T-cell_response_data_for_prostate_cancer_vaccine_Provenge\"><\/span>Dendreon touts T-cell response data for prostate cancer vaccine Provenge<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Dendreon has had no shortage of challenges with Provenge since winning FDA approval for the groundbreaking prostate cancer vaccine back in 2010. Years later, the company has unveiled new data showing the med generates a killer T-cell response\u2014and the strength of that response correlates with overall survival. In a Monday poster session at the American Society of Clinical Oncology\u2019s annual meeting, Dendreon showcased the new data showing that Provenge elicits a T-cell response to the immunizing antigen A2024 and to the target antigen prostatic acid phosphatase on prostate tumor cells. The responses were seen as early as six weeks after patients received Provenge and lasted for a minimum of six months, according to the company. Men with both hormone-sensitive prostate cancer and those with metastatic castrate-resistant prostate cancer (mCRPC) experienced the responses, which correlated with improved overall survival.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Johnson_Johnsons_Zytiga_slashes_death_risk_by_38_in_earlier-stage_prostate_cancer_patients\"><\/span>Johnson &amp; Johnson&#8217;s Zytiga slashes death risk by 38% in earlier-stage prostate cancer patients<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Johnson &amp; Johnson may soon be able to move prostate cancer med Zytiga into an earlier disease stage, thanks to game-changing new data that rolled out on Saturday at the American Society of Clinical Oncology (ASCO) annual meeting. Zytiga, in tandem with prednisone and androgen deprivation therapy, trounced an ADT-plus-placebo duo at improving survival among patients with high-risk metastatic hormone-na\u00efve prostate cancer, cutting the risk of death by 38%, J&amp;J said Saturday. Median overall survival for the Zytiga arm wasn\u2019t reached, while the placebo arm posted an average of 34.7 months. And that wasn\u2019t all. Zytiga also slashed the risk of progression or death by 53%, more than doubling the average time to one of those events from 14.8 months on ADT alone to 33 months on the J&amp;J med.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"AstraZenecas_Lynparza_posts_42_survival_win_in_breast_cancer\"><\/span>AstraZeneca&#8217;s Lynparza posts 42% survival win in breast cancer<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Back in February, AstraZeneca announced that its Lynparza had become the first PARP inhibitor to find success outside of ovarian cancer, posting positive results among breast cancer patients. And Sunday, the British drugmaker revealed just how positive those results were. In a phase 3 study comparing the medication with standard-of-care chemo in patients with HER2-negative breast cancer and BRCA1 or BRCA2 mutations, Lynparza pared down the risk of disease worsening or death by 42%, AZ said at the American Society of Clinical Oncology annual meeting. Tumors shrank in about 60% of patients treated with Lynparza, versus just 29% of those in the chemo arm of the study. And importantly, the med was \u201ceffective\u201d among patients with triple-negative breast cancer, which has proven notoriously difficult to treat.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Pfizers_two-time_loser_dacomitinib_finally_wins_in_phase_3_against_AstraZenecas_Iressa\"><\/span>Pfizer&#8217;s two-time loser dacomitinib finally wins in phase 3 against AstraZeneca&#8217;s Iressa<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Pfizer\u2019s EGFR lung cancer candidate, dacomitinib, doesn\u2019t have a pretty past. But the New York drugmaker has finally rung up a phase 3 victory. On Monday, the American Society of Clinical Oncology announced that dacomitinib had topped AstraZeneca\u2019s Iressa in delaying cancer growth in newly diagnosed patients, slashing the risk of progression or death by 41%. With dacomitinib, trial participants went a median 14.7 months without their cancer worsening, compared with 9.2 months on Iressa. Both drugs are part of the tyrosine kinase inhibitors (TKI) class of meds. It\u2019s the first positive set of phase 3 results for the Pfizer prospect, which flopped in two late-stage studies back in early 2014. In one, the med failed to improve progression-free survival compared with Roche\u2019s Tarceva, and in the other, also versus Tarceva, it couldn\u2019t significantly increase overall survival.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Roches_Alecensa_trounces_Pfizers_Xalkori_in_head-to-head_ALK_matchup\"><\/span>Roche&#8217;s Alecensa trounces Pfizer&#8217;s Xalkori in head-to-head ALK matchup<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Novartis\u2019 Zykadia just won the right to challenge Pfizer\u2019s Xalkori for the first-line ALK-positive lung-cancer crown. But the way Roche sees it, that crown is Alecensa\u2019s for the taking, as soon as it can nab an FDA approval, too. Monday at the American Society of Clinical Oncology annual meeting, the Swiss drugmaker\u2019s contender posted data showing it could beat Xalkori at cutting down the risk of disease worsening or death by more than 53%. Both drugs are targeted at lung tumors with an ALK gene rearrangement. Alecensa also led when it came to preventing brain metastases, which are more common among ALK-positive patients because it\u2019s an aggressive tumor. Patients in the Alecensa group recorded just a 9% incidence of brain metastases at the 12-month mark, while 41% of patients in the Xalkori arm developed them. Overall, the data are really clear in the sense that this will become the new standard of care for first-line.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dendreon touts T-cell response data for prostate cancer vaccine Provenge Dendreon has had no shortage of challenges with Provenge since winning FDA approval for the groundbreaking prostate cancer vaccine back in 2010. Years later, the company has unveiled new data showing the med generates a killer T-cell response\u2014and the strength of that response correlates with [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1965,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17533,5976,922,96,127,894,17532,921,460,639,498,524,17534,613],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-2159","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-alecensa","tag-alk","tag-asco2017","tag-astrazeneca","tag-breast-cancer","tag-dendreon","tag-iressa","tag-jj","tag-pfizer","tag-pharma-news","tag-prostate-cancer","tag-roche","tag-t-cell","tag-zytiga","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Dendreon touts; Zytiga slashes risk; Lynparza posts; Dacomitinib wins<\/title>\n<meta name=\"description\" content=\"Dendreon has had no shortage of challenges with Provenge since winning FDA approval for the groundbreaking prostate cancer vaccine....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-42\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dendreon touts; Zytiga slashes risk; Lynparza posts; Dacomitinib wins\" \/>\n<meta property=\"og:description\" content=\"Dendreon has had no shortage of challenges with Provenge since winning FDA approval for the groundbreaking prostate cancer vaccine....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-42\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-06-06T11:30:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/06175102\/news.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"960\" \/>\n\t<meta property=\"og:image:height\" content=\"520\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Dendreon touts; Zytiga slashes risk; Lynparza posts; Dacomitinib wins","description":"Dendreon has had no shortage of challenges with Provenge since winning FDA approval for the groundbreaking prostate cancer vaccine....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-42","og_locale":"en_US","og_type":"article","og_title":"Dendreon touts; Zytiga slashes risk; Lynparza posts; Dacomitinib wins","og_description":"Dendreon has had no shortage of challenges with Provenge since winning FDA approval for the groundbreaking prostate cancer vaccine....","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-42","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-06-06T11:30:29+00:00","article_modified_time":"2021-07-24T07:26:46+00:00","og_image":[{"width":960,"height":520,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/06175102\/news.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-42","url":"https:\/\/www.delveinsight.com\/blog\/notizia-42","name":"Dendreon touts; Zytiga slashes risk; Lynparza posts; Dacomitinib wins","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-42#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-42#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/06175102\/news.jpg","datePublished":"2017-06-06T11:30:29+00:00","dateModified":"2021-07-24T07:26:46+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Dendreon has had no shortage of challenges with Provenge since winning FDA approval for the groundbreaking prostate cancer vaccine....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-42"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-42#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/06175102\/news.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/06175102\/news.jpg","width":960,"height":520},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/06175102\/news-300x163.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alecensa<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ALK<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ASCO2017<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Breast Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Dendreon<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Iressa<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">J&amp;J<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Prostate Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">T Cell<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Zytiga<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alecensa<\/span>","<span class=\"advgb-post-tax-term\">ALK<\/span>","<span class=\"advgb-post-tax-term\">ASCO2017<\/span>","<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">Breast Cancer<\/span>","<span class=\"advgb-post-tax-term\">Dendreon<\/span>","<span class=\"advgb-post-tax-term\">Iressa<\/span>","<span class=\"advgb-post-tax-term\">J&amp;J<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Prostate Cancer<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">T Cell<\/span>","<span class=\"advgb-post-tax-term\">Zytiga<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jun 6, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jun 6, 2017 5:00 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2159","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2159"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2159\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1965"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2159"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2159"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2159"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2159"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2159"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}